NPPA warns IV fluid makers for non-submission of pricing data despite reminders
|
Shardul Nautiyal, Mumbai
May 27 , 2015
|
|
National Pharmaceutical Pricing Authority (NPPA) has directed the
manufacturers and marketing companies of IV fluids to submit data on
price-to-retailer (PTR) and moving annual total (MAT) value for
September 2013.
The drug regulator said non-compliance to the
said notification may lead to taking appropriate action. NPPA in its
recent notification reminded the manufacturers and marketing companies
on the same for September 2013. This is the third time NPPA has made a
request to the manufacturing and marketing companies to provide the
required data.
In its notification, NPPA said that its office has
not received requisite data or information along with copy of
supporting invoices from all concerned manufacturing and marketing
companies of IV fluid as sought for office memorandum dated March 4,
2015 and reminder dated March 27, 2015.
The drug price regulator
has asked all concerned companies to comply immediately with the office
memorandum and in absence of the required data, "NPPA would be
constrained to take appropriate action on the basis of available
information," the notification said.
NPPA, in another
notification earlier, had notified the price of various types of IV
fluids. "Various companies have represented to NPPA as well as filed
Review Petition before the government against the price notification
issued by NPPA. Considering the views raised by the companies, NPPA had
held meeting with IV fluid manufacturers, associations, Drug Controller
General of India (DCGI), Niper, etc," the earlier notification read. The
regulator had since then asked the companies to submit PTR and MAT
value for September 2013 by March 11, 2015, failing which NPPA would
take a final view based on the available data.
According to the
recent notification, however, it pointed out that the required data has
not yet been submitted by the concerned manufacturing and marketing
companies.
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|